ABBVIE INC. ABBV

AbbVie Inc. (AbbVie) es una empresa biofarmacéutica basada en la investigación. La compañía se dedica a la investigación y desarrollo, fabricación, comercialización y venta de medicamentos y terapias. AbbVie ofrece sus productos en diversas categorías terapéuticas, que incluyen productos de Inmunología, como Humira, Skyrizi y Rinvoq; productos de Oncología, como Imbruvica y Venclexta; productos de Estética, como Botox Cosmetic, Juvederm Collection y otros productos estéticos; productos de Neurociencia, como Botox Terapéutico, Vraylar, Duopa y Duodopa, y Ubrelvy; productos para el cuidado de los ojos, como Lumigan, Alphagan y Restasis; productos de salud de la mujer, como Lo Loestrin, Orilissa y otros productos para la salud de la mujer; y otros productos clave, que incluyen Mavyret, Creon, Lupron, Linzess y Synthroid. Los productos de la compañía se venden en todo el mundo directamente a mayoristas, distribuidores, agencias gubernamentales, instalaciones de atención médica y minoristas independientes desde los centros de distribución de propiedad de AbbVie y almacenes públicos.

Con 4 acciones de ABBV (USD 1.048,48) habrías recibido USD 27,32 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?

  AbbVie received FDA approval for Juvmo, a once-daily oral treatment for Parkinson's disease launching in October 2026. As the first selective D1/D5 dopamine receptor agonist usable as standalone or combination therapy, Juvmo expands AbbVie's PD portfolio alongside Vyalev and Duopa, with the three therapies expected to generate peak sales above $5 billion. The approval validates AbbVie's $8.7 billion Cerevel Therapeutics acquisition and strengthens its neuroscience segment, which grew 22% year-over-year.

  

• Zacks Investment Research 1 oct

  AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

  AbbVie is a trending stock with strong earnings growth expectations of +40.5% for the current fiscal year and +14.8% for next year. The company has consistently beaten consensus estimates over the trailing four quarters. However, with a Zacks Rank #3 (Hold) rating and a C valuation grade indicating it trades at par with peers, the stock is expected to perform in line with the broader market in the near term.

  

• Zacks Investment Research 1 oct

  ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?

  AbbVie's stock has gained 25.4% over six months, driven by strong growth from Skyrizi and Rinvoq, which are expected to generate over $31 billion in combined 2026 sales. The company is successfully navigating Humira's patent expiry through new immunology and neuroscience products. However, challenges include Humira biosimilar erosion, slowing oncology sales, and weakness in the Aesthetics business. Analysts recommend holding the stock (Zacks Rank #3) as long-term prospects remain intact with expected 10% revenue growth in 2026.

  

• The Motley Fool 30 sept

  AbbVie Stock: Buy, Sell, or Hold in October?

  AbbVie, a pharmaceutical giant with 53 consecutive years of dividend increases, remains a stable long-term investment despite losing U.S. patent exclusivity for its blockbuster drug Humira in 2023. The company has offset this decline through new immunology drugs (Skyrizi and Rinvoq) and strategic acquisitions including Allergan (Botox). Analysts project 9% revenue CAGR and 21% adjusted EPS CAGR from 2025-2028. At $264 per share with a 2.6% forward yield and 16x forward P/E, the stock is reasonably valued for buy-and-hold investors.

  

• The Motley Fool 29 sept

  Novo Nordisk Gives Uninspiring Outlook

  Novo Nordisk provided disappointing guidance to investors, forecasting a considerable slowdown in revenue growth. The company faces challenges including the patent cliff for its blockbuster drug Ozempic, which management acknowledged as a significant concern.